The product designated Combined Rabbit Viral Haemorrhagic Disease and Pasteurella multocida Vaccine, Inactivated Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is a bulk inactivated antigen concentrate rather than a finished immunotherapeutic. The active fraction comprises inactivated Rabbit Haemorrhagic Disease Virus RHDV, genus Lagovirus, and inactivated Pasteurella multocida bacterial antigen, with residual cell debris or purified outer membrane fractions depending on the downstream processing route. No harmonised international model number is assigned; the manufacturer-specific article code and the lot release protocol constitute the operative identity. The multiple dosage form designation does not imply equal biological feasibility. Injectable presentations are the conventional route, while tablets, capsules, powders, granules, premixes, and oral solutions require formulation-specific stability and antigen-release validation because the gastrointestinal environment of the rabbit is destructive to bacterial antigens. The concentrate is manufactured under EU GMP Annex 1 for sterile veterinary active substances where injectable grade is claimed, and under relevant VICH stability testing principles for product-specific expiry assignment.

The RHDV component is a non-enveloped, icosahedral calicivirus classified in the genus Lagovirus; RHDV2/GI.2 has broader host range and altered antigenic profile relative to classical RHDV/GI.1. P. multocida is an encapsulated Gram-negative coccobacillus; capsular types A and D are frequently implicated in rabbit respiratory disease. Commercial inactivation of RHDV typically uses beta-propiolactone or binary ethyleneimine, while P. multocida bacterins are commonly prepared with formaldehyde. Specific reagent concentrations and inactivation time-temperature profiles for this combined concentrate are not harmonised in any public monograph; published data for this specific configuration is limited. Release therefore depends on manufacturer-defined inactivation kinetics, antigen recovery, and batch-to-batch consistency rather than a single international numerical identity.

Composition and Monograph Alignment of the Combined Inactivated Antigen Concentrate

In liquid injectable presentation, the aqueous phase is commonly a phosphate-buffered saline solution with pH 6.5–7.5. Aluminium hydroxide adjuvant is used at 1.0–3.0 mg Al³+/mL to adsorb the P. multocida fraction; RHDV particles may remain partly unadsorbed because their surface charge does not always favour electrostatic binding to the adjuvant at physiological ionic strength. The formulation must therefore be characterised for antigen distribution between adjuvant pellet and supernatant. For the bacterial fraction, adsorption efficiency is typically set at not less than 80% after centrifugation at 15,000 × g for 20 min, but product-specific acceptance limits are taken from the current pharmacopoeial dossier. The concentrate should be filtered through a 0.22 µm membrane before adjuvant addition, because adjuvanted suspensions are not filterable and terminal steam sterilisation is incompatible with proteinaceous antigens.

Production-scale inactivation vessels are constructed from 316L stainless steel with bottom-mounted magnetic drive mixing. RHDV inactivation by beta-propiolactone is pH- and temperature-dependent; the hydrolysis of beta-propiolactone to beta-hydroxypropionic acid produces a downward pH drift that must be controlled by automatic addition of sodium hydroxide. Inactivation temperature is held within ±0.5 °C of the target set point. Incomplete pH control leads either to incomplete inactivation or to antigen damage. The bacterial fraction is prepared from P. multocida cultures in tryptic soy broth or equivalent, inactivated with formaldehyde, concentrated by tangential-flow filtration, and stored as a sterile suspension before pooling with the viral antigen. The pooled concentrate is then sterile-filtered through a 0.22 µm membrane before any adjuvant addition.

Quantitative identity for RHDV is commonly assigned by ELISA or haemagglutination-inhibition using rabbit erythrocytes. The antigen titre is expressed as ELISA units per millilitre or haemagglutination titre per millilitre, but no harmonised minimum for this combined concentrate exists in the public domain. P. multocida antigen is measured by protein assay or specific ELISA against capsular type A or D antigen. Batch-to-batch variance is controlled by normalising each lot to a reference standard; the coefficient of variation for repeat analytical runs is typically held below 15%. If any single release test exceeds its specified acceptance range, the lot is not designated injectable and may be diverted to non-parenteral development studies only after documented risk assessment.

The lyophilised presentation, if requested for tablets, capsules, or dry powder blends, requires a collapse temperature below the primary drying shelf temperature. A conservative primary drying shelf temperature between -30 °C and -10 °C with vacuum between 50–200 µbar is typical for viral and bacterial antigen lyophilisates, but no published data for this specific combined concentrate establishes a fixed cycle. Residual moisture above 3.0% w/w shortens rehydrated antigen integrity and increases batch-to-batch variation in dry powder flow. Mannitol or trehalose in the excipient phase is used to protect the RHDV capsid from ice-crystal damage; sucrose is also used to stabilise the bacterial outer membrane proteins during freezing. The exact cryoprotectant ratio is product-specific and not interchangeable with standard chemical API lyocycles.

What Limits Oral Solid Dosage Feasibility for an Inactivated RHDV-P. multocida Antigen Concentrate?

The principal constraint is the gastrointestinal barrier. RHDV is a non-enveloped virus and tolerates acidic pH, but P. multocida outer membrane proteins and capsular polysaccharides are acid-labile and protease-sensitive. Rabbit gastric pH can fall to 1.0–2.0; residence times in the stomach and small intestine are short but sufficient to reduce bacterial antigen integrity unless enteric coating or microencapsulation is used. Standard enteric coatings based on polymethacrylate derivatives dissolve above pH 5.5–6.8, which can protect antigen in the stomach but does not guarantee release at gut-associated lymphoid tissue sites in the rabbit distal small intestine. Compression into tablets exposes lyophilised antigen to shear and local heating; direct compression pressures above 80 MPa are generally avoided for protein- and antigen-bearing powders due to loss of tertiary structure. Published data for this specific configuration is limited.

Powders, granules, and premixes intended for feed incorporation face a different limiting step: feed pelleting. Conditioning and pelleting at temperatures above 70 °C for more than a few seconds can denature bacterial antigens and reduce RHDV capsid stability; the P. multocida fraction is usually the loss-limiting analyte. If the API is to survive feed manufacturing, a protected granule or post-pelleting spraying application is required, or the product is limited to mash feed or drinking water reconstitution at ambient temperature. Relative humidity during dry blending should be kept below 30% RH because hygroscopic excipients and residual moisture accelerate antigen degradation. These constraints are not present in the injectable presentation, which is why injectable use remains the reference route for potency studies.

Rabbit gastrointestinal physiology differs from canine or porcine models. The rabbit stomach has a low fasting pH but continuously secretes acid; the small intestine is the primary site for Peyer’s patch sampling. Oral antigen delivery in rabbits is hampered by rapid transit through the small intestine and by the lack of a robust hydrolytic barrier for proteins. Published data for this specific configuration is limited, so veterinary formulators should not extrapolate from rodent oral vaccine results. If oral tablet or capsule development is pursued, a pharmacopoeial dissolution apparatus with pH-shift media from 1.2 to 6.8 is used as a screening tool, but the method is only a surrogate for rabbit gut antigen release and does not establish immunogenicity.

For injectable finished product, the manufacturing sequence is sensitive to order of addition. The RHDV-containing aqueous fraction is filtered through a 0.22 µm membrane; the sterile aluminium hydroxide gel is then added under low-shear mixing. High-shear mixing above 500 rpm is avoided because it can strip adsorbed P. multocida antigen and generate fine aluminium particles that fail visual inspection. The adjuvanted suspension is filled into multidose glass or polymer vials with a nitrogen overlay to limit oxidation. Batch-to-batch variance in antigen content is typically controlled by ELISA or haemagglutination-inhibition for RHDV and by ELISA or quantitative bacterin recovery for P. multocida; no harmonised potency value exists in the public domain for this combined concentrate.

Cleaning validation in multi-product veterinary antigen facilities is a further operational boundary. RHDV is a non-enveloped virus and resists many disinfectants; sodium hypochlorite at 0.5% available chlorine or sodium hydroxide at 1.0 M is commonly used for decontamination of processing equipment, with contact times not less than 30 min. P. multocida is susceptible to standard quaternary ammonium compounds but the combined product must be treated as a viral-bacterial mixed system for line cleaning. These conditions should be captured in the facility’s contamination control strategy under EU GMP Annex 15 and ISO 14644-1 cleanliness classification for aseptic operations. Failure modes on production lines include foaming during adjuvant transfer, filter plugging with bacterial ghosts, and sedimentation in filling line tubing; these are controlled by line-speed reduction and stainless-steel vessel geometry rather than by increasing shear.

Storage, Preservative Compatibility, and Operational Boundaries

The concentrate should be stored at 2–8 °C in a dark, temperature-mapped cold room. Freezing is contraindicated; freeze-thaw cycles precipitate aluminium hydroxide and disrupt the bacterial antigen fraction. Light exposure should be limited because formaldehyde-inactivated bacterins can undergo photolytic changes in residual carbonyl compounds. The aqueous liquid is stable only within a narrow pH window; pH below 6.0 or above 8.0 accelerates hydrolysis of bacterial outer membrane proteins. Antimicrobial preservatives, if required for multidose finished vials, must be selected carefully. Benzalkonium chloride at concentrations above 0.01% m/v may reduce P. multocida antigen integrity. Thiomersal is generally compatible with inactivated RHDV at trace concentrations but its use is restricted in food-producing animals in some jurisdictions. Phosphate buffers above 50 mM should be avoided when aluminium hydroxide adjuvant is present, because high phosphate can displace adsorbed antigen and alter the gel’s point of zero charge.

Incompatibility with amine-based additives should be noted; primary amine excipients can cause premature crosslinking of any residual formaldehyde-inactivated bacterial antigen and generate antigen-aggregate particles that fail visual inspection. The product should not be blended with live attenuated vaccines or live bacterial cultures unless a compatibility study under the final container closure has been performed. Where tablets or capsules are dry-formulated, desiccant inserts and aluminium foil blister packaging with a cold-forming film are used to maintain the low moisture environment. No terminal sterilisation by gamma irradiation or electron beam should be applied to the lyophilised concentrate because ionising radiation degrades RHDV capsid proteins and lipopolysaccharide-associated antigens. Published data for this specific combined product under industrial irradiation is limited, so the operational limitation is considered absolute for routine manufacturing.

Solutions are the only form suitable for parenteral use. For oral drinking water application, the concentrate is diluted in buffered water at pH 6.5–7.5 and used within 24 hours to avoid microbial overgrowth and antigen loss. The solution should not be exposed to chlorine concentrations above 0.5 ppm; chlorine oxidises bacterial antigens and can reduce RHDV capsid integrity. This is a practical limitation in farm water supplies that rely on chlorination.

In field use, injectable presentations are typically administered subcutaneously or intramuscularly to rabbits from breeding or production units; the primary course and revaccination interval are set by local marketing authorisation and not by the API manufacturer. Compared with live attenuated RHDV vaccines, the inactivated combined concentrate removes vaccinal virus shedding and reversion risk, which is a material consideration in multi-age rabbitries. Compared with monovalent P. multocida bacterins, the combined product reduces injection events but introduces antigenic competition that must be evaluated in potency assays; a poor P. multocida response may not be evident until challenge. Compared with autogenous P. multocida vaccines, the combined product uses reference strains rather than farm-specific isolates, which may reduce protection against local capsular type A or D variants. These differences make the API form suitable as a manufacturing intermediary for licensed veterinary products, but not as a direct substitute for a farm-specific immunological diagnosis.